Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
about
Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report.Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer.Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.Stricturing Crohn's disease-like colitis in a patient treated with belatacept.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.Management of adverse events related to checkpoint inhibition therapy.The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature reviewImmune Checkpoint Inhibitor-Associated Colits and Hepatitis
P2860
Q36260666-8D017C12-BA59-4A3E-AA63-27B640DC8837Q39017623-9391D095-FBD6-4D6A-BF15-59AA0C7961AFQ40262479-5F694C6D-F15D-44CB-81F0-EFB867605532Q41989035-8F83D7C5-7874-41AB-873B-FAF89DD99F51Q42374962-CCE6A6A6-DC30-4C01-BEC6-74ACAD22E62CQ47102520-912663CC-26FA-4472-80B8-04436FC12C79Q47304240-B682CD32-E203-4517-9BDB-08177204D7FFQ47734760-0BA8370D-753E-4F67-831E-9A5D25A66336Q48369113-CF830E5D-50D7-4156-B642-15E2868E8E32Q49861796-A34A8CCC-33DB-40D0-9BCD-EB0E16BBA0EEQ50205173-47D3D235-F0E0-4837-AF48-E38DE4E48B8CQ53723979-DFAEDC14-63D6-4CAA-A4C7-1EB3F6CB8940Q55233801-D4E72762-6274-4351-92DB-843F4309391AQ55314300-F2415C8A-4C7A-4AD1-81CB-E126D93A1011Q55419474-F708ADFF-4ED2-45C1-8203-7FB7F22E60CAQ56889607-CB788B85-FE1C-4668-BBF8-3D099A845079Q58721137-7B8AD04B-7D59-45C6-8D76-E4995553B715
P2860
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cancer Immunotherapy with Anti ...... an Inflammatory Bowel Disease.
@en
Cancer Immunotherapy with Anti ...... an Inflammatory Bowel Disease.
@nl
type
label
Cancer Immunotherapy with Anti ...... an Inflammatory Bowel Disease.
@en
Cancer Immunotherapy with Anti ...... an Inflammatory Bowel Disease.
@nl
prefLabel
Cancer Immunotherapy with Anti ...... an Inflammatory Bowel Disease.
@en
Cancer Immunotherapy with Anti ...... an Inflammatory Bowel Disease.
@nl
P2093
P2860
P50
P921
P356
P1476
Cancer Immunotherapy with Anti ...... an Inflammatory Bowel Disease.
@en
P2093
D Planchard
E Soularue
F Carbonnel
J F Rahier
P2860
P304
P356
10.1093/ECCO-JCC/JJV227
P577
2016-01-18T00:00:00Z